The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations
The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations, including institutions in Seoul, Republic of Korea; Nanjing, China; Michigan; New York and Louisiana. The newly accredited organizations are:
“These latest accreditations demonstrate the increasing recognition that AAHRPP accreditation is the mark of excellence for human research protection programs, here and around the globe,” said Elyse Summers, AAHRPP president and CEO. “AAHRPP accreditation signifies an organization’s commitment to the highest level of research protections—all to the benefit of the research participants we are pledged to protect.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. Accreditation decisions are made quarterly. They continue at a steady pace, reflecting strong interest in every sector of the research enterprise, in the U.S. and abroad.
To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Singapore and Taiwan. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.